NRx Pharmaceuticals Reschedules Q2 2025 Financial Results Release to August 19, 2025

NRx Pharmaceuticals reschedules its Q2 2025 financial results release to August 19, 2025, with a conference call on August 20, 2025. The company requires additional time to compile information into the Form 10-Q, including recent developments. The conference call will be available on the company's website, and participants can dial in domestically or internationally to join.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has announced a delay in the release of its second quarter 2025 financial results. The company has rescheduled the release to August 19, 2025, after the market close, with a subsequent conference call scheduled for August 20, 2025, at 8:00 AM ET [2].

The rescheduling is due to the need for additional time to compile certain information and recent developments into the Form 10-Q filing. Investors can access the results via a press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestically) or +1-646-307-1865 (internationally) [2].

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 and NRX-101 receiving Fast Track and Breakthrough Therapy Designations, respectively [1].

References:
[1] https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-2025-financial-results-on-august-14-2025
[2] https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-second-quarter-2025-rspkrmpuj7cv.html